Sansure Biotech Inc.
Símbolo: 688289.SS
SHH
20.62
CNYPrecio de mercado actual
31.0215
Ratio PER
0.0048
Ratio PEG
11.83B
Capitalización MRK
- 0.03%
Rendimiento DIV
Sansure Biotech Inc. (688289-SS) Estados Financieros
Balance de situación
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 4781.8 | 5663.8 | 4682.7 | |||||||
balance-sheet.row.short-term-investments | 0 | 548.3 | 2451.2 | 2046.5 | |||||||
balance-sheet.row.net-receivables | 0 | 732.8 | 1472.7 | 894.1 | |||||||
balance-sheet.row.inventory | 0 | 376.6 | 355.3 | 369.5 | |||||||
balance-sheet.row.other-current-assets | 0 | 58.4 | 33.6 | 20 | |||||||
balance-sheet.row.total-current-assets | 0 | 5949.6 | 7525.4 | 5966.2 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1055.2 | 785.3 | 481 | |||||||
balance-sheet.row.goodwill | 0 | 7.7 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 328 | 84.4 | 45.6 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 335.6 | 84.4 | 45.6 | |||||||
balance-sheet.row.long-term-investments | 0 | 974.3 | -1793.8 | -1533.2 | |||||||
balance-sheet.row.tax-assets | 0 | 73.8 | 69.6 | 25 | |||||||
balance-sheet.row.other-non-current-assets | 0 | 65.6 | 2502.8 | 2105.8 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 2504.6 | 1648.3 | 1124.1 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 8454.2 | 9173.8 | 7090.4 | |||||||
balance-sheet.row.account-payables | 0 | 468.7 | 791.4 | 258.7 | |||||||
balance-sheet.row.short-term-debt | 0 | 77.2 | 14.3 | 8.5 | |||||||
balance-sheet.row.tax-payables | 0 | 17.7 | 216.4 | 101.3 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 18.2 | 13.6 | 6.4 | |||||||
Deferred Revenue Non Current | 0 | 32.5 | 30.5 | 25.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 340.5 | 712.9 | 2.4 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 77.7 | 89.3 | 45.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 18.2 | 13.6 | 6.4 | |||||||
balance-sheet.row.total-liab | 0 | 996.8 | 1661 | 709 | |||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 588.5 | 588.5 | 400 | |||||||
balance-sheet.row.retained-earnings | 0 | 4882.7 | 5077.1 | 3820 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 395.2 | 377.4 | 294 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1334.9 | 1457.7 | 1854.9 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 7201.3 | 7500.6 | 6368.9 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 8454.2 | 9173.8 | 7090.4 | |||||||
balance-sheet.row.minority-interest | 0 | 223.6 | 12.2 | 12.4 | |||||||
balance-sheet.row.total-equity | 0 | 7424.9 | 7512.8 | 6381.3 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 1522.6 | 657.4 | 513.2 | |||||||
balance-sheet.row.total-debt | 0 | 95.4 | 27.9 | 14.9 | |||||||
balance-sheet.row.net-debt | 0 | -4138 | -3184.7 | -2621.3 |
Estado de tesorería
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 1936.7 | 2242.5 | 2616.6 | ||||||
cash-flows.row.depreciation-and-amortization | 0 | 89.1 | 53.9 | 26.7 | ||||||
cash-flows.row.deferred-income-tax | 0 | -40 | -8.1 | -4.6 | ||||||
cash-flows.row.stock-based-compensation | 0 | 60.8 | 5.6 | 4.6 | ||||||
cash-flows.row.change-in-working-capital | 0 | 203.3 | -402.1 | -50.4 | ||||||
cash-flows.row.account-receivables | 0 | -496.5 | -304.1 | -419.4 | ||||||
cash-flows.row.inventory | 0 | -282.1 | -93 | -212.1 | ||||||
cash-flows.row.account-payables | 0 | 496.5 | 3.1 | 585.7 | ||||||
cash-flows.row.other-working-capital | 0 | 485.4 | -8.1 | -4.6 | ||||||
cash-flows.row.other-non-cash-items | 0 | 308.9 | -14.8 | 49.4 | ||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -558.8 | -372.9 | -108.7 | ||||||
cash-flows.row.acquisitions-net | 0 | -11.6 | 15.9 | 115 | ||||||
cash-flows.row.purchases-of-investments | 0 | -12140.6 | -7880 | -3725 | ||||||
cash-flows.row.sales-maturities-of-investments | 0 | 11591.1 | 7125.6 | 2111.3 | ||||||
cash-flows.row.other-investing-activites | 0 | -46.9 | -0.9 | -108.7 | ||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -1166.7 | -1112.2 | -1716 | ||||||
cash-flows.row.debt-repayment | 0 | -17.2 | -55 | -55 | ||||||
cash-flows.row.common-stock-issued | 0 | 274.6 | 200 | 0 | ||||||
cash-flows.row.common-stock-repurchased | 0 | -257.4 | -200 | 0 | ||||||
cash-flows.row.dividends-paid | 0 | -656.9 | -439.9 | -301.3 | ||||||
cash-flows.row.other-financing-activites | 0 | -259 | -193.7 | 1966.2 | ||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -915.9 | -688.6 | 1609.9 | ||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -10 | -34.3 | -44.6 | ||||||
cash-flows.row.net-change-in-cash | 0 | 466.2 | 42 | 2491.6 | ||||||
cash-flows.row.cash-at-end-of-period | 0 | 3099.1 | 2632.8 | 2590.8 | ||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 2632.8 | 2590.8 | 99.2 | ||||||
cash-flows.row.operating-cash-flow | 0 | 2558.9 | 1877.1 | 2642.3 | ||||||
cash-flows.row.capital-expenditure | 0 | -558.8 | -372.9 | -108.7 | ||||||
cash-flows.row.free-cash-flow | 0 | 2000.1 | 1504.2 | 2533.6 |
Fila de la Cuenta de Resultados
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1002.5 | 6450.4 | 4514.5 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 381.8 | 2655.4 | 1279 | |||||||
income-statement-row.row.gross-profit | 0 | 620.7 | 3795 | 3235.5 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 10.6 | 95.5 | 44.5 | |||||||
income-statement-row.row.operating-expenses | 0 | 638.7 | 1262.2 | 666.9 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 1020.5 | 3917.5 | 1945.9 | |||||||
income-statement-row.row.interest-income | 0 | 54.7 | 48.4 | 32.5 | |||||||
income-statement-row.row.interest-expense | 0 | 2.4 | 2.1 | 0.8 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 450.7 | -23.9 | -5.6 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 10.6 | 95.5 | 44.5 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 450.7 | -23.9 | -5.6 | |||||||
income-statement-row.row.interest-expense | 0 | 2.4 | 2.1 | 0.8 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 136.8 | 290.8 | -20.7 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | -18 | 2339.8 | 2621.8 | |||||||
income-statement-row.row.income-before-tax | 0 | 432.6 | 2315.9 | 2616.2 | |||||||
income-statement-row.row.income-tax-expense | 0 | 62.3 | 379.2 | 373.7 | |||||||
income-statement-row.row.net-income | 0 | 363.7 | 1936.8 | 2242.7 |
Preguntas frecuentes
Cuánto es Sansure Biotech Inc. (688289.SS) activos totales?
Sansure Biotech Inc. (688289.SS) los activos totales son 8454204974.000.
¿Cuáles son los ingresos anuales de la empresa?
Los ingresos anuales son N/A.
¿Cuál es el margen de beneficios de la empresa?
El margen de beneficios de la empresa es 0.729.
¿Qué es el flujo de caja libre de la empresa?
El flujo de caja libre es -0.496.
¿Cuál es el margen de beneficio neto de la empresa?
El margen de beneficio neto es 0.321.
¿Cuáles son los ingresos totales de la empresa?
Los ingresos totales son 0.334.
¿Qué es Sansure Biotech Inc. (688289.SS) beneficio neto (ingresos netos)?
El beneficio neto (ingresos netos) es 363721131.000.
¿Cuál es la deuda total de la empresa?
La deuda total es 95444005.000.
¿Cuál es la cifra de gastos de explotación?
Los gastos de explotación son 638676546.000.
¿Cuál es la cifra de tesorería de la empresa?
La tesorería de la empresa es 0.000.